| 2026-04-29 |
财报披露：
美东时间 2026-04-29 盘前发布财报
|
| 2026-02-19 |
详情>>
内部人交易：
Zoghbi Huda Y共交易7笔
|
| 2026-02-04 |
详情>>
股本变动：
变动后总股本10571.98万股
|
| 2026-02-04 |
详情>>
业绩披露：
2025年年报每股收益43.07美元,归母净利润45.05亿美元,同比去年增长2.09%
|
| 2025-11-20 |
复牌提示：
2025-11-19 16:05:00 停牌，复牌日期 2025-11-19 16:30:00
|
| 2025-10-28 |
详情>>
业绩披露：
2025年三季报(累计)每股收益34.83美元,归母净利润36.60亿美元,同比去年增长4.73%
|
| 2025-08-01 |
详情>>
业绩披露：
2025年中报每股收益20.78美元,归母净利润22.00亿美元,同比去年增长2.14%
|
| 2025-04-29 |
股东大会：
将于2025-06-13召开股东大会
会议内容 ▼▲
- 1.Elect four Class I directors for a three-year term
2.Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025
3.Cast an advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in these proxy materials (say-on-pay)
4.Approve an amendment to the Company’s Certificate of Incorporation to declassify the board of directors
5.Approve two amendments to the Company’s Certificate of Incorporation to eliminate supermajority vote requirements
6.Act upon such other matters as may properly come before the meeting and any adjournment(s) or postponement(s) thereof
|
| 2025-04-29 |
详情>>
业绩披露：
2025年一季报每股收益7.58美元,归母净利润8.09亿美元,同比去年增长12.01%
|
| 2025-02-05 |
详情>>
业绩披露：
2022年年报每股收益40.51美元,归母净利润43.38亿美元,同比去年增长-46.28%
|
| 2025-02-05 |
详情>>
业绩披露：
2024年年报每股收益40.90美元,归母净利润44.13亿美元,同比去年增长11.61%
|
| 2024-10-31 |
详情>>
业绩披露：
2023年三季报(累计)每股收益26.16美元,归母净利润27.94亿美元,同比去年增长-11.06%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益32.36美元,归母净利润34.95亿美元,同比去年增长25.09%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益19.95美元,归母净利润21.54亿美元,同比去年增长20.61%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益6.70美元,归母净利润7.22亿美元,同比去年增长-11.71%
|
| 2024-04-25 |
股东大会：
将于2024-06-14召开股东大会
会议内容 ▼▲
- 1.To elect four Class III directors for a three-year term and one Class II director for a two-year term;
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To cast an advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in these proxy materials (say-on-pay);
4.If properly presented, to vote on a non-binding shareholder proposal;
5.To act upon such other matters as may properly come before the meeting and any adjournment(s) or postponement(s) thereof.
|
| 2024-02-05 |
详情>>
业绩披露：
2023年年报每股收益37.05美元,归母净利润39.54亿美元,同比去年增长-8.87%
|
| 2023-04-21 |
股东大会：
将于2023-06-09召开股东大会
会议内容 ▼▲
- 1.To elect four Class II directors for a three-year term;
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To cast an advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in these proxy materials (say-on-pay);
4.To cast an advisory vote on whether future say-on-pay votes should be held every one, two, or three years (say-on-frequency);
5.If properly presented, to vote on a non-binding shareholder proposal;
6.To act upon such other matters as may properly come before the meeting and any adjournment(s) or postponement(s) thereof.
|
| 2023-04-21 |
股东大会：
将于2023-06-09召开股东大会
会议内容 ▼▲
- 1.To elect four Class II directors for a three-year term;
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To cast an advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in these proxy materials (say-on-pay);
4.To cast an advisory vote on whether future say-on-pay votes should be held every one, two, or three years (say-on-frequency);
5.If properly presented, to vote on a non-binding shareholder proposal;
6.To act upon such other matters as may properly come before the meeting and any adjournment(s) or postponement(s) thereof.
|
| 2022-04-21 |
股东大会：
将于2022-06-10召开股东大会
会议内容 ▼▲
- 1.to elect four Class I directors for a three-year term;
2.to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.to cast an advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in these proxy materials (say-on-pay);
4.to act upon such other matters as may properly come before the meeting and any adjournment(s) or postponement(s) thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-06-08 |
股东大会：
将于2020-06-12召开股东大会
会议内容 ▼▲
- 1.to elect four Class II directors for a three-year term and one Class III direcor for a one-year term;
2.to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.to approve the Second Amended and Reatated Regeneron Pharmaceuticals, Inc 2014 Long-term Incentive Plan;
4.to cast an advisory vote to approve the compensation of the company's Named Executive Officers as disclosed in these proxy materials (say on pay)
5.to act upon such other matters as may properly come before the meeting and any adjournment(s) or postponement(s) thereof.
|
| 2019-04-26 |
股东大会：
将于2019-06-14召开股东大会
会议内容 ▼▲
- 1.to elect four Class I directors for a term of three years;
2.to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.to act upon such other matters as may properly come before the meeting and any adjournment(s) or postponement(s) thereof.
|
| 2018-04-23 |
股东大会：
将于2018-06-08召开股东大会
会议内容 ▼▲
- 1.to elect three Class III directors for a term of three years;
2.to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.to act upon such other matters as may properly come before the meeting and any adjournment(s) or postponement(s) thereof.
|
| 2017-04-25 |
股东大会：
将于2017-06-09召开股东大会
会议内容 ▼▲
- 1.to elect five Class II directors for a term of three years and one Class I director for a term of two years;
2.to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.to approve the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan, which approval shall also constitute approval for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, of certain performance goals in the Plan that may apply to awards thereunder;
4.to cast an advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in these proxy materials (say on pay);
5.to cast an advisory vote on whether future say-on-pay votes should be held every one, two, or three years (say on frequency);
6.to act upon such other matters as may properly come before the meeting and any adjournment(s) or postponement(s) thereof.
|
| 2016-04-26 |
股东大会：
将于2016-06-10召开股东大会
会议内容 ▼▲
- (1)to elect three Class I directors for a term of three years;
(2)to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016;
(3)to act upon such other matters as may properly come before the meeting and any adjournment(s) or postponement(s) thereof.
|